Researcher
Tim Lammens
- Keywords:acute myeloid leukemi, inherited predisposition for cancer, asparaginase, neuroblastoma, juvenile myelomonocytic leukemia, pediatric oncology
- Disciplines:Molecular and cell biology not elsewhere classified, Oncology not elsewhere classified, Genomics, Paediatrics
Affiliations
- Department of Internal Medicine and Pediatrics (Department)
Member
From1 Oct 2018 → Today - Department of Pediatrics and medical genetics (Department)
Member
From1 Jun 2009 → 30 Sep 2018 - Department of Plant Biotechnology and Bioinformatics (Department)
Member
From1 Oct 2004 → 31 Jan 2009
Projects
1 - 10 of 14
- Research assignment of Prof. dr. Tim Lammens, framing the ongoing clinical-translational research at the Department of Pediatric Hematology-Oncology and Stem Cell TransplantationFrom1 Oct 2023 → TodayFunding: Nonprofit institution or equivalents
- Preclinical validation of a less toxic variant for paediatric leukemiaFrom1 Oct 2022 → Today
- Stichting Me to You - Research Grant Derpoorter Charlotte: "Evaluation of PCLO as a specific and novel therapeutic target in pediatric B-cell acute lymphoblastic leukemia"From14 Sep 2022 → TodayFunding: Foundations, funds and other with scientific goal
- A patient derived xenograft (PDX) platform for in vivo evaluation of novel anticancer therapiesFrom1 May 2022 → TodayFunding: FWO Medium Size Research Infrastructure
- The impact of magnetic particulate matter (mPM) pollution as a contributing factor for development of childhood cancer: an in vitro and in vivo molecular and cellular analysis.From1 Nov 2021 → 31 Oct 2022Funding: Nonprofit institution or equivalents
- Preclinical evaluation of newly identified therapeutic targets in pediatric acute myeloid leukemiaFrom1 Oct 2021 → TodayFunding: Nonprofit institution or equivalents
- The use of a less toxic alternative asparaginase variant to treat metastatic breast cancerFrom1 Oct 2021 → TodayFunding: BOF - projects
- Preclinical study of TARP-directed cellular and nanobody therapy in pediatric AML: improving survival and quality-of-lifeFrom1 Nov 2020 → TodayFunding: Nonprofit institution or equivalents
- Minimal residual disease targeting in T-cell acute lymphoblastic leukemiaFrom1 Oct 2020 → 23 Sep 2022Funding: BOF - postdoctoral mandates
- Predisposition in a family with two pediatric patients with Hodgkin lymphoma Non-BurkettFrom1 Jun 2016 → 31 May 2018Funding: Foundations, funds and other with scientific goal
Publications
1 - 10 of 125
- In vivo stabilization of a less toxic asparaginase variant leads to a durable antitumor response in acute leukemia(2023)
Authors: Maaike Van Trimpont, Amanda M. Schalk, Yanti De Visser, Hien Anh Nguyen, Lindy Reunes, Katrien Vandemeulebroecke, Evelien Peeters, Ying Su, Hyun Lee, Philip L. Lorenzi, et al.
Pages: 409 - 419 - European standard clinical practice : key issues for the medical care of individuals with familial leukemia(2023)
Authors: Alisa Förster, Claudia Davenport, Nicolas Duployez, Miriam Erlacher, Alina Ferster, Jude Fitzgibbon, Gudrun Göhring, Henrik Hasle, Marjolijn C. Jongmans, Alexandra Kolenova, et al.
- In vivo stabilization of a less toxic asparaginase variant leads to a durable anti-tumor response in acute leukemia(2023)
Authors: Maaike Van Trimpont, Amanda M. Schalk, Yanti De Visser, Hien Anh Nguyen, Lindy Reunes, Katrien Vandemeulebroecke, Evelien Peeters, Ying Su, Hyun Lee, Philip L. Lorenzi, et al.
Pages: 409 - 419 - Correction to : functional classification of RUNX1 variants in familial platelet disorder with associated myeloid malignancies(2022)
Authors: Melanie Decker, Tim Lammens, Alina Ferster, Miriam Erlacher, Ayami Yoshimi, Charlotte M. Niemeyer, Martijn P. T. Ernst, Marc H. G. P. Raaijmakers, Nicolas Duployez, Andreas Flaum, et al.
Pages: 2949 - 2949 - Novel insights on the use of L-asparaginase as an efficient and safe anti-cancer therapy(2022)
Authors: Maaike Van Trimpont, Evelien Peeters, Yanti De Visser, Amanda M. Schalk, Veerle Mondelaers, Barbara De Moerloose, Arnon Lavie, Tim Lammens, Steven Goossens, Pieter Van Vlierberghe
- Predicting outcomes with circulating adrenergic neuroblastoma mRNAs in children with relapsed and refractory neuroblastoma : a BEACON-Neuroblastoma biomarker study(2022)Volume: 40
Authors: Lucas Moreno, Rebekah Weston, Virginie Viprey, Andrei Tchirkov, Maria Corrias, Tim Lammens, Juliet Gray, Cormac Owens, Jennifer Laidler, Marion Gambart, et al.
Number of pages: 1 - The feasibility of using liquid biopsies as a complementary assay for copy number aberration profiling in routinely collected paediatric cancer patient samples(2022)
Authors: Ruben Van Paemel, Charlotte Vandeputte, Lennart Raman, Jolien Van Thorre, Leen Willems, Jo Van Dorpe, Malaïka Van der Linden, Jilke De Wilde, Andries De Koker, Björn Menten, et al.
Pages: 12 - 23 - Practice guidelines for the therapeutic drug monitoring of asparaginase in acute lymphoblastic leukemia(2022)
Authors: Veerle Mondelaers, Tim Lammens, Martijn de Jong, Larissa Deneweth, Katrien Vandemeulebroecke, Barbara De Moerloose
Pages: 236 - 242 - A clinically annotated post-mortem approach to study multi-organ somatic mutational clonality in normal tissues(2022)
Authors: Tom Luijts, Kerryn Elliott, Joachim Siaw, Joris Van de Velde, Elien Beyls, Arne Claeys, Tim Lammens, Erik Larsson, Wouter Willaert, Anne Vral, et al.
- Mutational permutations of a single amino acid exert divergent phenotypic effects in human, mice and cellular models of SAMD9L bone marrow failure disorder(2022)
Authors: Sushree S Sahoo, Charnise Goodings-Harris, Shondra Miller, Maria Angeles Lillo Osuna, Baranda S Hansen, Lei Han, Ti-Cheng Chang, Tim Lammens, Mattias Hofmans, Marta Derecka, et al.
Number of pages: 1